問卷

TPIDB > Outstanding PI

Outstanding PI

HuangLi-Min
  • National Taiwan University Hospital
  • Division of Pediatrics

    未分科

查看完整簡歷

Highlights

Number of Clinical Trials 74

1. Global leading PI: Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2022, doi:10.1016/s0140-6736(22)00313-0. 2. Great contribution to Pediatric Infectious Diseases 3. Early phase small-molecule drug/vaccine development
ChiuCheng-Hsun
  • Linkou Chang Gung Medical Foundation
  • CHANGHUA CHRISTIAN HOSPITAL
  • Division of Pediatrics

    未分科

    Division of Infectious Disease

查看完整簡歷

Highlights

Number of Clinical Trials 68

JongYuh-Jyh
  • Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital
  • Division of Pediatrics

    未分科

查看完整簡歷

Highlights

Number of Clinical Trials 26

NIYEN-HSUAN
  • National Taiwan University Hospital
  • Division of Pediatrics

    Digestive System Department

    Division of General Internal Medicine

    未分科

查看完整簡歷

Highlights

Number of Clinical Trials 67

1.The diet therapy of inflammatory bowel disease: a multi-omic analysis − Inflammatory Bowel Disease (IBD) − Crohn's Disease − Nutrition therapy microbiota − Crohn's disease exclusion diet 2. Study to Evaluate Efficacy and Safety of MS-20 on Patients with Ulcerative Colitis − Ulcerative colitis − MS-20 3. Minimize the Risk of Infection-Related Cancers by Implementation of Microbiota Reprogramming − HBV − HIV − HPV − nasopharngeal carcinoma − microbiology 4. Development of novel anti-allergic probiotics by gut microbiota metagenomic analysis in infant cohorts − Allergic diseases − Gut microbiota − metabolites − Prebiotics − Probiotics 5. A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis − Ulcerative colitis − Pediatric 6. Explore the biomarkers determining the evolution of liver fibrosis and the outcome of pediatric chronic liver disease − Microbiota 7. Gut microbiota play a critical role in determining the age-dependent outcome of hepatitis B virus infection − Microbiota 8. The oncofetal RBMY protein and gut microbiota dysbiosis facilitate the development and metastasis of hepatocellular carcinoma − Hepatocellular Carcinoma (HCC) − Metastasis − microbiota − Epithelial–Mesenchymal Transition 9. Explore the clinical impacts of cell-free DNA as a noninvasive diagnosis of liver injury in pediatric liver transplant patients − Liver transplant 10. Development of precision microbiome-based interventions in chronic hepatitis B − Chronic hepatitis B − Gut microbiota
ChenShih-Hsiang
  • Linkou Chang Gung Medical Foundation
  • Division of Pediatrics

    Division of Hematology & Oncology

查看完整簡歷

Highlights

Number of Clinical Trials 13